The reduced RIPK3 expression in cancers contrasts that in inflammatory diseases, which often exhibit increased RIPK3 expression.47, 48 This suggests that the primary effect of reduced RIPK1 and RIPK3 expression in colon cancers may be to minimize anti-cancer immune activation. This evidence concerns the gene RIPK1 and malignant colon neoplasm.